MedPath

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3
Completed
Conditions
Uterine Fibroids
Heavy Menstrual Bleeding
Interventions
Drug: Placebo to match OBE2109
Drug: Add-back
Drug: Placebo to match Add-back
Registration Number
NCT03070899
Lead Sponsor
ObsEva SA
Brief Summary

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Detailed Description

The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with add-back therapy for the treatment of uterine fibroids.

Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
526
Inclusion Criteria
  • Premenopausal woman at screening.
  • Body Mass Index ≥ 18 kg/m2.
  • Menstrual cycles ≥ 21 days and ≤ 40 days.
  • Presence of uterine fibroids.
  • Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.

Key

Exclusion Criteria
  • The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • History of uterus surgery that would interfere with the study.
  • The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.
  • Undiagnosed abnormal uterine bleeding.
  • Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-backOBE2109-
OBE2109 dose 1 (100mg) + Add-backOBE2109-
OBE2109 dose 1 (100mg) + Add-backPlacebo to match OBE2109-
OBE2109 dose 1 (100mg) + Placebo Add-backOBE2109-
OBE2109 dose 1 (100mg) + Placebo Add-backPlacebo to match OBE2109-
OBE2109 dose 1 (100mg) + Add-backAdd-back-
OBE2109 dose 2 (200mg) + Add-backOBE2109-
OBE2109 dose 1 (100mg) + Placebo Add-backPlacebo to match Add-back-
Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-backPlacebo to match Add-backAt W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-backPlacebo to match Add-back-
OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-backAdd-back-
OBE2109 dose 2 (200mg) + Add-backAdd-back-
Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-backOBE2109At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-backAdd-backAt W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-backPlacebo to match OBE2109At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
Primary Outcome Measures
NameTimeMethod
Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24From baseline to Week 24

Assessed using the alkaline hematin method

Secondary Outcome Measures
NameTimeMethod
AmenorrheaUp to Week 52

Assessed using the alkaline hematin method

Number of days of uterine bleeding for the last 28-day interval prior to Week 24last 28-day interval prior to Week 24

Assessed using the alkaline hematin method

Number of days of uterine bleeding for each 28-day intervalUp to Week 52

Assessed using the alkaline hematin method

Time to reduced menstrual blood lossUp to Week 52

Assessed using the alkaline hematin method

Time to amenorrheaUp to Week 52

Trial Locations

Locations (116)

Site reference ID 169

🇺🇸

Dothan, Alabama, United States

Site reference ID 183

🇺🇸

Dallas, Texas, United States

Site reference ID 109

🇺🇸

Marrero, Louisiana, United States

Site reference ID 248

🇺🇸

Frederick, Maryland, United States

Site reference ID 185

🇺🇸

Los Angeles, California, United States

Site reference ID 157

🇺🇸

Houston, Texas, United States

Site reference ID 219

🇺🇸

Houston, Texas, United States

Site reference ID 217

🇺🇸

Houston, Texas, United States

Site reference ID 236

🇺🇸

Las Vegas, Nevada, United States

Site reference ID 137

🇺🇸

Miami, Florida, United States

Site reference ID 142

🇺🇸

Miami, Florida, United States

Site reference ID 110

🇺🇸

Miami, Florida, United States

Site reference ID 106

🇺🇸

Miami, Florida, United States

Site reference ID 127

🇺🇸

Miami, Florida, United States

Site reference ID 354

🇺🇸

Wichita, Kansas, United States

Site reference ID 178

🇺🇸

Shawnee Mission, Kansas, United States

Site reference ID 101

🇺🇸

San Diego, California, United States

Site reference ID 172

🇺🇸

San Antonio, Texas, United States

Site reference ID 242

🇺🇸

Phoenix, Arizona, United States

Site reference ID 145

🇺🇸

Detroit, Michigan, United States

Site reference ID 186

🇺🇸

Cincinnati, Ohio, United States

Site reference ID 192

🇺🇸

Birmingham, Alabama, United States

Site reference ID 238

🇺🇸

Austin, Texas, United States

Site reference ID 155

🇺🇸

Austin, Texas, United States

Site reference ID 123

🇺🇸

Richmond, Virginia, United States

Site reference ID 166

🇺🇸

Sacramento, California, United States

Site reference ID 189

🇺🇸

New Haven, Connecticut, United States

Site reference ID 140

🇺🇸

Orlando, Florida, United States

Site reference ID 113

🇺🇸

Tampa, Florida, United States

Site reference ID 119

🇺🇸

Winston-Salem, North Carolina, United States

Site reference ID 232

🇺🇸

Vestavia Hills, Alabama, United States

Site reference ID 353

🇺🇸

Mobile, Alabama, United States

Site reference ID 355

🇺🇸

Tucson, Arizona, United States

Site reference ID 154

🇺🇸

Huntington Park, California, United States

Site reference ID 211

🇺🇸

Arcadia, California, United States

Site reference ID 147

🇺🇸

Escondido, California, United States

Site reference ID 184

🇺🇸

Cerritos, California, United States

Site reference ID 199

🇺🇸

Northridge, California, United States

Site reference ID 111

🇺🇸

Panorama City, California, United States

Site reference ID 144

🇺🇸

Denver, Colorado, United States

Site reference ID 239

🇺🇸

Upland, California, United States

Site reference ID 234

🇺🇸

Thornton, Colorado, United States

Site reference ID 112

🇺🇸

Westminster, California, United States

Site reference ID 246

🇺🇸

Englewood, Colorado, United States

Site reference ID 105

🇺🇸

Washington, District of Columbia, United States

Site reference ID 190

🇺🇸

Boca Raton, Florida, United States

Site reference ID 233

🇺🇸

DeLand, Florida, United States

Site reference ID 146

🇺🇸

Hialeah, Florida, United States

Site reference ID 204

🇺🇸

Loxahatchee Groves, Florida, United States

Site reference ID 191

🇺🇸

Jacksonville, Florida, United States

Site reference ID 117

🇺🇸

Miami Lakes, Florida, United States

Site reference ID 129

🇺🇸

Miami Springs, Florida, United States

Site reference ID 107

🇺🇸

Miramar, Florida, United States

Site reference ID 124

🇺🇸

New Port Richey, Florida, United States

Site reference ID 141

🇺🇸

Orlando, Florida, United States

Site reference ID 163

🇺🇸

Columbus, Georgia, United States

Site reference ID 207

🇺🇸

Saint Petersburg, Florida, United States

Site reference ID 150

🇺🇸

Sandy Springs, Georgia, United States

Site reference ID 158

🇺🇸

Norcross, Georgia, United States

Site reference ID 352

🇺🇸

Meridian, Idaho, United States

Site reference ID 174

🇺🇸

Champaign, Illinois, United States

Site reference ID 182

🇺🇸

Oak Brook, Illinois, United States

Site reference ID 359

🇺🇸

Idaho Falls, Idaho, United States

Site reference ID 176

🇺🇸

Lake Charles, Louisiana, United States

Site reference ID 226

🇺🇸

Silver Spring, Maryland, United States

Site reference ID 228

🇺🇸

Towson, Maryland, United States

Site reference ID 126

🇺🇸

Fall River, Massachusetts, United States

Site reference ID 100

🇺🇸

Bay City, Michigan, United States

Site reference ID 214

🇺🇸

Saginaw, Michigan, United States

Site reference ID 170

🇺🇸

Saginaw, Michigan, United States

Site reference ID 138

🇺🇸

Missoula, Montana, United States

Site reference ID 175

🇺🇸

Brooklyn, New York, United States

Site reference ID 188

🇺🇸

New York, New York, United States

Site reference ID 245

🇺🇸

Lawrenceville, New Jersey, United States

Site reference ID 133

🇺🇸

Staten Island, New York, United States

Site reference ID 131

🇺🇸

Morehead City, North Carolina, United States

Site reference ID 208

🇺🇸

Port Jefferson, New York, United States

Site reference ID 187

🇺🇸

Southern Pines, North Carolina, United States

Site reference ID 104

🇺🇸

Greensboro, North Carolina, United States

Site reference ID 213

🇺🇸

Franklin, Ohio, United States

Site reference ID 230

🇺🇸

Fairfield, Ohio, United States

Site reference ID 102

🇺🇸

Raleigh, North Carolina, United States

Site reference ID 164

🇺🇸

Cleveland, Ohio, United States

Site reference ID 116

🇺🇸

Bryn Mawr, Pennsylvania, United States

Site reference ID 222

🇺🇸

Indiana, Pennsylvania, United States

Site reference ID 165

🇺🇸

Jenkintown, Pennsylvania, United States

Site reference ID 210

🇺🇸

Pittsburgh, Pennsylvania, United States

Site reference ID 148

🇺🇸

Smithfield, Pennsylvania, United States

Site reference ID 351

🇺🇸

North Charleston, South Carolina, United States

Site reference ID 358

🇺🇸

Spartanburg, South Carolina, United States

Site reference ID 235

🇺🇸

Knoxville, Tennessee, United States

Site reference ID 159

🇺🇸

Chattanooga, Tennessee, United States

Site reference ID 205

🇺🇸

Memphis, Tennessee, United States

Site reference ID 180

🇺🇸

Memphis, Tennessee, United States

Site reference ID 201

🇺🇸

Beaumont, Texas, United States

Site reference ID 247

🇺🇸

Corpus Christi, Texas, United States

Site reference ID 216

🇺🇸

Dallas, Texas, United States

Site reference ID 200

🇺🇸

Dallas, Texas, United States

Site reference ID 250

🇺🇸

Fort Worth, Texas, United States

Site reference ID 244

🇺🇸

Fort Worth, Texas, United States

Site reference ID 115

🇺🇸

Frisco, Texas, United States

Site reference ID 120

🇺🇸

Houston, Texas, United States

Site reference ID 218

🇺🇸

Pasadena, Texas, United States

Site reference ID 128

🇺🇸

Webster, Texas, United States

Site reference ID 125

🇺🇸

West Jordan, Utah, United States

Site reference ID 171

🇺🇸

Norfolk, Virginia, United States

Site reference ID 103

🇺🇸

Norfolk, Virginia, United States

Site reference ID 237

🇺🇸

Bellevue, Washington, United States

Site reference ID 197

🇺🇸

Fort Lauderdale, Florida, United States

Site reference ID 195

🇺🇸

Hershey, Pennsylvania, United States

Site reference ID 231

🇺🇸

Boca Raton, Florida, United States

Site reference ID 168

🇺🇸

Clearwater, Florida, United States

Site reference ID 149

🇺🇸

Fall River, Massachusetts, United States

Site reference ID 135

🇺🇸

Hialeah, Florida, United States

Site reference ID 134

🇺🇸

Miami Lakes, Florida, United States

Site reference ID 151

🇺🇸

Norcross, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath